熱門資訊> 正文

Emergsti Pharma GAAP每股收益为-1.35美元

2024-06-21 21:17

Acasti製藥(ACST) 0

Acasti Pharma press release (NASDAQ:ACST): FY GAAP EPS of -$1.35.
At March 31, 2024, the Company had cash and cash equivalents of $23.0 million, as compared to $27.9 million as of March 31, 2023. The Company believes it has sufficient cash to support operations into the second calendar quarter of 2026.

More on Acasti Pharma

Seeking Alpha’s Quant Rating on Acasti Pharma
Historical earnings data for Acasti Pharma
Financial information for Acasti Pharma

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。